Impact of COVID pandemic on Pharmacovigilance in the MENA region, updates and expectations



In Collaboration With:

Covid-19 has impacted activities globally across society including pharmacovigilance without any end date to this pandemic.
Regulators have provided expectations during this crisis but what are the practical implications?
This webinar will reflect on range of questions that arise including:

  • How should we adjust our priorities and where should we be extra vigilant?
  • How long do business continuity plans last before quality systems must be changed?
  • Are there opportunities for more efficient practice leading to more efficient pharmacovigilance


Dr. Brian Edwards

MD MRCP, Principal Consultant
Pharmacovigilance & Drug Safety, NDA Regulatory Science, UK

Shahinaz Badr

Regional Pharmacovigilance Manager
NewBridge Pharmaceuticals

Marianne Mounir

PVCH Middle East and Saudi
QPPV coordination Lead, Bayer Egypt